Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vaxil BioTherapeutics logo — A pioneering clinical-stage firm advancing synthetic vaccine...

Vaxil BioTherapeutics

A pioneering clinical-stage firm advancing synthetic vaccines that activate both T and B-cells using proprietary technology.

Founded 2007 11-50 employees Biotechnology, Health Care +1

General Information

Company Name Vaxil BioTherapeutics
Founded Year 2007
Employees 11-50
Industries Biotechnology, Health Care, Health and Wellness
Social

Get notified when Vaxil BioTherapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vaxil BioTherapeutics

Vaxil BioTherapeutics is a pioneering clinical-stage firm in the biotechnology industry, focusing on advancing synthetic vaccines that activate both T and B-cells using its proprietary VaxHit technology. Founded in 2007, Vaxil BioTherapeutics Ltd. (TASE:VAXL) is on a mission to create a pioneering class of synthetic therapeutic and preventive vaccines specifically designed to activate antigen-specific T and B cells. The company's dedication to advancing vaccine technology makes it a promising player in the biotechnology sector. However, specific details about its headquarters, last investment, and investors are currently unavailable. Vaxil BioTherapeutics holds significant potential in the field of immunotherapy and its innovative approach positions it as a key player in the industry.

Taxonomy: Clinical-stage company, Synthetic vaccines, T and B-cell activation, VaxHit technology, Immunotherapy, Multiple Myeloma, Cancer Vaccines

No funding data available for Vaxil BioTherapeutics yet.

Get notified when Vaxil BioTherapeutics raises funding

Vaxil BioTherapeutics Alternatives & Competitors

Vaxil BioTherapeutics vs
Tréidlia Biovet
Tréidlia Biovet Australia

Designing Specialised Biotechnological Solutions for Animal Health

54 employees
Biotechnology, Pharmaceutical
Vaxil BioTherapeutics vs
Bavarian Nordic
Bavarian Nordic Denmark

Biopharmaceutical company developing cancer immunotherapies and vaccines against infectious diseases

IPO
1714 employees
Vaxil BioTherapeutics vs
MEVAC for Vaccines
MEVAC for Vaccines Egypt

Science , Innovation , Quality

298 employees
Health Care

FAQ About Vaxil BioTherapeutics

A pioneering clinical-stage firm advancing synthetic vaccines that activate both T and B-cells using proprietary technology.
Vaxil BioTherapeutics was founded in 2007.
Vaxil BioTherapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Vaxil BioTherapeutics has approximately 11-50 employees.
Top alternatives and competitors to Vaxil BioTherapeutics include Tréidlia Biovet, Bavarian Nordic, MEVAC for Vaccines , Livingston Pediatrics, Braasch Biotech LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vaxil BioTherapeutics and Tréidlia Biovet are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vaxil BioTherapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes